1. ImmunityBio Inc. (NASDAQ:IBRX)
Stock Upside Potential: 79.21%
Year-to-Date Gain: 268.32%
ImmunityBio, Inc. has delivered the strongest performance on the list, driven by rapid commercialization of its lead product and accelerating revenue growth.
On April 9, the company reported preliminary results for the quarter ending March 31, 2026, showing product revenue of $44.2 million, up 168% year-over-year. The growth is driven by the launch of ANKTIVA, an FDA-approved treatment for non-muscle invasive bladder cancer.
The company generated $113 million in product revenue in 2025, representing a 700% increase compared to 2024. It exited the quarter with $380.9 million in cash and cash equivalents, providing a strong liquidity position to support expansion.
ANKTIVA has been approved across five jurisdictions covering 34 countries. Adoption continues to increase as physicians integrate the therapy into treatment protocols. The company is now focused on scaling in the U.S. and expanding internationally.
ImmunityBio’s platform targets activation of natural killer cells and T cells, positioning it in the immunotherapy space. With an approved product already generating revenue and a pipeline for future indications, the company combines growth, commercialization, and high upside potential.
READ ALSO: Top 10 Penny Stocks That Could Turn $1,000 Into $1 Million and Top 10 Cheap Robotics Stocks To Buy Now.
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
